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Abstract: Omega-3 fatty acids are essential for brain growth and development. They play 
an important role throughout life, as critical modulators of neuronal function and regulation 
of oxidative stress mechanisms, in brain health and disease. Docosahexanoic acid (DHA), the 
major omega-3 fatty acid found in neurons, has taken on a central role as a target for therapeutic 
intervention in Alzheimer’s disease (AD). A plethora of in vitro, animal model, and human 
data, gathered over the past decade, highlight the important role DHA may play in the devel-
opment of a variety of neurological and psychiatric disorders, including AD. Cross sectional 
and prospective cohort data have demonstrated that reduced dietary intake or low brain levels 
of DHA are associated with accelerated cognitive decline or the development of incipient 
dementia, including AD. Several clinical trials investigating the effects of omega-3 fatty acid 
supplementation in AD have been completed and all failed to demonstrate its efficacy in the 
treatment of AD. However, these trials produced intriguing data suggesting that the beneficial 
effects of omega-3 fatty acid supplementation may depend on the stage of disease, other dietary 
mediators, and apolipoprotein E status.
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Introduction
Alzheimer’ disease (AD) is a progressive neurodegenerative disorder that represents 
the major cause of dementia in the world today.1 Over 5 million persons in the US 
currently suffer from this fatal disease and that number is expected to quadruple by the 
year 2050, unless prevention efforts or disease modifying therapies are developed.1,2 
The annual costs of care for persons with AD severely tax the health care system today, 
and are predicted to singlehandedly create a future health care crisis.
AD is characterized clinically by the development of early amnestic and execu-
tive dysfunction, that eventually spreads across cognitive domains, that leads to the 
complete incapacity and development of end-stage dementia.3 The major pathological 
hallmarks of AD are extracellular amyloid (Aβ) plaque deposition and intraneuronal 
neurofibrillary tangle formation.4–6 Emerging evidence suggests that progressive 
inflammation and increased oxidative stress play a key role in the early development 
of such pathological features.7–12 Such mechanisms have also been clearly posited to 
play a key role in synaptic dysfunction and the loss of neuronal integrity that may 
precede the overt appearance of amyloid plaques and neurofibrillary tangles in the 
brains of affected individuals.
Cellular pathways involved in the homeostasis and regulation of brain fatty acids 
are central players in both the inflammatory and oxidative stress cascades implicated Clinical Interventions in Aging 2010:5 46
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in the pathogenesis of AD.7,8 The present review highlights 
the latest discoveries in the basic biology of omega-3 fatty 
acids in the brain in the animal model, in vitro, and human 
data, on the relationship of omega-3 fatty acids with AD, 
and clinical trial results using omega-3 fatty acids for the 
treatment of AD. Furthermore, these findings are synthesized 
into a rationale strategy that may help guide the future use 
of omega-3 fatty acid supplementation in the management 
or prevention of early AD.
Fatty acids in the brain
Fatty acids serve as both energy substrates and integral mem-
brane components essential for proper neuronal and brain 
function.7–10,12–14 Triglycerides are the substrate for energy 
metabolism in low glucose states, while polyunsaturated 
fatty acids (PUFA) are integral membrane lipids that serve 
to maintain both the structure and function of neuronal mem-
branes, membrane associated proteins and protein complexes. 
The incorporation of PUFA into neuronal membranes lowers 
the total cholesterol fraction, leading to increased membrane 
fluidity that is essential to maintain synaptic structures 
(Figure 1).15 As a result of PUFA incorporation increased 
membrane fluidity can increase the number and affinity of 
receptors in the synapse and improve neurotransmission. 
Such fluidity is important in promoting synaptic plasticity 
that is essential for learning, memory, and other complex 
cognitive processes.
PUFAs are also converted into essential membrane phos-
pholipids and second messengers that modulate inflammation, 
oxidative stress, and neuronal health.7,8,10,12,13,16,17 Long chain 
PUFAs in the brain include both omega-3 PUFAs, (eg, doc-
osahexanoic acid [DHA, 22:6n3]), and omega-6 PUFAs 
(eg, arachidonic acid [AA, 20:4n6]). PUFAs such as DHA 
and AA are created through hydrolysis mediated crosslinking 
(double bond formation) along the carbonyl backbone of their 
saturated fatty acid precursors. This chemical structure pro-
motes increased stability and membrane fluidity that allows 
unique protein lipid interactions not otherwise afforded by 
saturated fatty acids or omega-6 fatty acids such as AA and 
cholesterol. As such, PUFAs have been identified as integral 
Saturated fatty acid  Cholesterol 
Polyunsaturated 
fatty acid (PUFA)  Saturated fatty acid  Cholesterol 
Receptor or 
ion channel 
Figure 1 Polyunsaturated fatty acids increase membrane fluidity and facilitate incorporation of essential membrane bound proteins required for synapse and lipid raft formation
A) Saturated fatty acids and cholesterol pack tightly to form a more rigid and less fluid lipid bilayer. B) Double-bond formation in polyunsaturated fatty acids creates a “bend” in the 
fatty acid tail that prevents the tight packing of saturated fatty acids and cholesterol leading to increased membrane fluidity and incorporation of integral synaptic proteins.Clinical Interventions in Aging 2010:5 47
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membrane components required for lipid raft formation that 
is essential for membrane and membrane-bound protein trans-
port, synapse formation, and neuronal membrane integrity.7–9 
In contrast to AA, which is distributed equally across gray and 
white matter areas in the brain, DHA is found predominantly 
in neuronal membranes in the gray matter and constitutes the 
major omega-3 fatty acid in the brain.17
DHA may also play a key role in both the structure and 
function of brain regions involved in the formation of new 
memories. Hippocampal DHA levels have been directly asso-
ciated with dietary intake, and higher levels have been shown 
to enhance hippocampal-dependent learning processes.18 
DHA has also been linked to the recently described phe-
nomena of hippocampal neurogenesis in the adult brain.19,20 
The role of DHA in this process is modulated through the 
expression of basic helix-loop-helix transcription factors in 
neuronal stem cells originating in the dentate gyrus.21 Altera-
tions in gene expression induced by DHA help to promote 
cell cycle exit and allow neuronal differentiation to occur. 
Enhanced neurogenesis in such regions has been postulated 
to lead to increased neuronal density and function in this 
critical circuitry for new memory formation. High dietary 
intake of omega-3 PUFAs has been directly associated with 
increased gray matter volume in corticolimbic circuitry 
that represents the affective input for memory formation 
and cortical arousal in the brain.22 Anterior cingulate, right 
amygdala and right hippocampal volumes were all correlated 
with increased omega-3 PUFA intake after correction for 
total brain volumes.22 The finding of selectivity of this effect 
for the right amygdala and hippocampus is unusual given 
that the proposed mechanisms for DHA augmentation of 
neurogenesis, new synapse formation, and increased gray 
matter volume should not be hemisphere dependent.19,21 This 
finding is intriguing given the recent neuroimaging data that 
suggest the asymmetric involvement of neuronal loss and 
degeneration in the hippocampus of research subjects with 
AD.23–27 Further work is clearly needed in this area before 
definite conclusions can be drawn.
DHA is considered an essential PUFA as de novo produc-
tion is not possible in humans. Eicosapentanoic acid (EPA, 
20:5n3) and α-linoleic acid (ALA, 18:3n3) can be converted 
to DHA by some cell types and organ systems in the body, 
however, there is great variability in the degree to which this 
can be accomplished in humans. While ALA can be derived 
from terrestrial plants and is commonly found in a Western 
or terrestrial-based diet, DHA and EPA, initially created by 
photosynthetic microalgae, are exclusively derived from 
marine animals. Little EPA or ALA is found in the brains 
of humans, again attesting to the importance of DHA in the 
maintenance of neuronal membrane integrity and the signal-
ing cascades related to PUFAs in the brain. Ratios of omega-6 
to omega-3 PUFAs may be as important as absolute levels 
of these lipids in the homeostasis of central nervous system 
(CNS) inflammation and oxidative stress. Induction of the 
pro-inflammatory AA cascade of signaling events exerts a 
negative influence on the downstream oxidative stress modu-
lation cascades dependent on DHA and its derivatives, and 
vice versa. It is intriguing that the dramatic increase in the 
prevalence of AD over the last century not only parallels the 
increase in average lifespan, but also an increase from 2 to 
more than 20 of the ratio of omega-6 to omega-3 PUFAs in 
the average Western diet.17,28
While much is known about the role of AA in the gen-
eration of the eicosanoids including the prostaglandins by 
cyclooxygenases (COX) and their role in initiating and 
maintaining the inflammatory cascade in the brain and other 
tissues, the critical role(s) of DHA and other omega-3 PUFAs 
are just beginning to be understood.10,12–14,17,28 Analogous to 
the formation of the eicosanoids from COX actions on AA, 
DHA is modified through phospholipase A2 and lipoxygen-
ase to form the docosanoid, neuroprotectin 1 (NPD1, see 
Figure 2).13,29,30 Several studies have demonstrated reduced 
activity of phospholipase A2 in brain tissue, cerebrospinal 
fluid CSF and platelet fractions from AD subjects.31–36 Such 
alterations in this critical enzyme required for the production 
of NPD1 may play a significant role in the development of 
AD. The formation of NPD1 from DHA is tightly regulated 
by the redox state of neurons. Increased oxidative stress 
caused by Aβ exposure, hypoxia, and interleukin (IL)-1β 
activity upregulates phospholipase A2 generating NPD1, 
which exerts a powerful negative feedback mechanism to 
control excessive oxidative stress. The actions of DHA and 
NPD1 additionally include upregulation of the Bcl-2 family 
of anti-apoptotic proteins, down regulation of pro-apoptotic 
signaling pathways, and inhibition of the pro-inflammatory, 
COX-mediated, production of eicosanoids, including pros-
taglandin synthesis from AA, which can further contribute 
to neuronal injury and destruction in degenerative diseases 
such as AD. Further elucidation of the molecular mechanisms 
through which increases in NPD1 and other metabolites of 
DHA enhance neuronal health is important for understanding 
how decreased levels of these important signaling molecules 
may contribute to the pathogenesis of AD and other degen-
erative diseases.
PUFAs are powerful antioxidants that are also readily oxi-
dized in a nonenzymatic fashion when subjected to excessive Clinical Interventions in Aging 2010:5 48
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neuronal oxidative stress.12 Nonenzymatic oxidation of AA 
results in the formation of the biologically active hydroxynon-
enal F2 isoprostanes (F2IsoPs).12,37 DHA is similarly oxidized 
to the biologically active hydroxyhexenal F4 neuroprostanes 
(F4NPs), so named because of their exclusive reflection of 
the redox state of neuronal populations in the brain.12,13 Early 
studies showed that F2 IsoPs and F4NPs were increased in 
the brains and ventricular fluid of autopsied, late stage, AD 
patients compared with controls.38–43 A later study showed 
increased F2IsoPs and F4NPs in the brains of mild cognitive 
impairment (MCI) patients compared to normal controls.11 
This study indicates the oxidative damage of AA and DHA is 
an early event in the pathogenesis of AD. The F2IsoPs, F4NPs, 
and other oxidative derivatives of PUFAs not only serve as 
important markers of oxidative stress in neurodegenerative 
diseases such as AD, they also adopt new biological activities 
and certain derivatives can enhance Aβ oligomerization 
in vitro. The usefulness of assays for F2 IsoPs and F4 NPs 
as biomarkers for therapeutic trials investigating PUFA and 
other antioxidative compounds may prove valuable to assess 
the biological efficacy of such strategies irrespective of the 
outcome of primary clinical endpoints.
DHA and Aβ
The amyloid cascade hypothesis of AD pathogenesis holds 
as a basic tenet the early formation of toxic amyloid-beta 
(Aβ) fragments from the normal cellular, transmembrane, 
amyloid precursor protein (APP).44,45 Release of toxic Aβ 
fragments leads to the early formation of soluble dimeric and 
oligomeric aggregates, that directly inhibit synaptic function 
and are highly toxic to neurons.46 Further aggregation leads 
to the formation of insoluble macromolecular complexes that 
Plasma membrane 
Phospholipase A2
DHA
15-Lipoxygenase
NPD1 a)  Pro-apoptotic 
proteins
Bcl-2, Bcl-xL,…ect. 
b) Anti-apoptotic 
proteins
Bax, Bad, Bid, Bik, 
caspase-3,…ect.
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proteins
COX-2, IL-1B,…ect. 
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Figure 2 Phospholipase A2 lipoxygenase forms neuroprotectin D1 (NPD1) from membrane bound DHA. Downstream effects of NPD1 include a) down regulation of pro-
apoptotic signaling pathways, b) upregulation of the bcl-2 family of anti-apoptotic proteins, c) inhibition of cyclooxygenase mediated production of inflammatory eicosanoids.Clinical Interventions in Aging 2010:5 49
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deposit in the extracellular milieu of the brain parenchyma to 
form amyloid plaques, a key pathological hallmark of AD. The 
combination of the toxic effects of both early soluble oligomers 
and insoluble plaque deposits of Aβ leads to further neuronal 
disruption and eventual cell death which in turn is responsible 
for the irreversible cognitive decline found in AD.
APP is normally processed by two membrane-associated, 
catalytic proteases, α- and β-secretase. Such proteolytic cleav-
age leads to the formation of harmless peptide fragments that 
are readily degraded further or shed from the CNS. In AD, 
a third membrane associated protease, γ-secretase, cleaves 
APP within the transmembrane portion of the protein. This 
cleavage combined with the extracellular cleavage of APP by 
β-secretase, which appears to be the rate-limiting enzyme in 
this degenerative pathway, releases the toxic Aβ peptide in a 
characteristic 40 or 42 amino acid form.47–51 While amyloid 
plaques are composed predominantly of 42 amino acid frag-
ments, the 40 amino acid fragment appears to accumulate in 
small arterioles and capillaries in the brain leading to cerebral 
amyloid angiopathy, increased risk of cerebral hemorrhage 
and the impairment of nutrient exchange, that all have a 
potential role in reducing the transport of essential PUFAs 
across the blood brain barrier. Such a role is speculative at 
present and deserves further study.
A wealth of data collected from in vitro assays, cell culture 
systems, and transgenic animal models of AD supports a direct 
association of omega-3 PUFAs, especially DHA, with amyloid 
processing in the brain.9,10,52–55 Omega-3 PUFAs as integral 
membrane components may act to alter amyloidogenic process-
ing in several distinct and possibly interrelated ways including: 
a) facilitate the interaction of α-secretase with APP to produce 
nontoxic fragments and prevent the formation of Aβ; b) shield 
the essential recognition sequence and intramembrane cleavage 
site for γ-secretase; c) serve as a local sink for free radicals that 
reduce the enzymatic augmentation of γ-secretase activity, that 
can be induced by free radical damage to the protein complex, 
which is important for the regulation of normal γ-secretase 
function; d) directly inhibit fibrillation and formation of toxic 
oligomeric species of Aβ (Figure 3).7,8,10,52,53
Cell culture studies consistently demonstrate a lowering 
of Aβ production by 20% after treatment with DHA.13,56 The 
activities of both β- and γ-secretase are down-regulated in DHA 
treated cultures and these effects appear to be directly related 
to the composition of lipid rafts that allow both the association 
and regulation of these critical enzymes in the formation of 
toxic Aβ.9,13,54,57 Additional studies have demonstrated increases 
in anti-apoptotic proteins of the Bcl-2 family, translocation and 
phosphorylation of Akt, and down-regulation of caspase-3 and 
9 in DHA cultured neurons, which are likely mediated by the 
formation of NPD1 (as described above).9,13 Such downstream 
effects of DHA supplementation are highly desirable in the 
interference of cellular mechanisms suggested to play a role 
in the pathogenesis of AD.
Transgenic animal models that develop amyloid plaque 
and vascular Aβ deposits allow further study of the poten-
tially beneficial effects of omega-3 PUFA supplementation 
in the abrogation of AD-like pathology. Studies have been 
done in several different model systems including the widely 
used and well characterized Tg2576,58,59 APPswe/PS1dE9,56 
and 3xTg-AD mice55 (Frank LaFerla’s triple transgenic 
mice). Nontransgenic mice infused with Aβ have also been 
used as a model system to investigate the beneficial effects 
of omega-3 PUFA supplementation.60–62 The experimental 
paradigm for treatment is as easy as altering the fatty acid 
composition of the diet used to feed the animals. A universal 
finding in every study using amyloid producing transgenic 
mice to date is a significant decrease in Aβ42 levels, with 
several studies also demonstrating decreases in Aβ40 and 
total Aβ levels. Tg2576 mice treated with omega-3 PUFA 
supplementation have universally shown reduced plaque 
numbers, while APPswe/PS1dE9 mice have not, despite 
the finding of reduced Aβ in these animals. A complete 
explanation for this discrepancy has not been reported, 
but may be related to the more aggressive time course of 
Aβ deposition in the APPswe/PS1dE9 mice (6 months) 
compared to the later development of amyloid pathology in 
Tg2576 mice (9–12 months). Green and colleagues dem-
onstrated decreased presenilin 1 (γ-secretase) in the triple 
transgenic mice as a result of DHA supplementation.55 Calon 
and colleagues investigated apoptotic regulators and found 
decreases in bipolar affective disorder and increases in PI3 
and Akt kinase pathways.58 Alterations in lipid raft and 
membrane composition as well as fluidity of the membrane 
in synaptosomal preparations have been well characterized 
in the Aβ40-infused Wistar rats.60,63
Comparing the studies is difficult due to the use of dif-
ferent dosing regimens, variations in treatment length, het-
erogeneity in animal model system, and outcome measures. 
Despite these problems and caveats, these animal models 
have proved useful and provide valuable insights into the 
effects of omega-3 PUFA supplementation on the develop-
ment of AD-like pathologic features, formation of Aβ frag-
ments, oxidative stress markers, secretase activity, regulation 
of pro- and anti-apoptotic proteins, membrane fluidity, and 
lipid raft composition, and performance on behavioral tasks 
such as the Morris water maze.Clinical Interventions in Aging 2010:5 50
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PUFA, cholesterol, and 
cerebrovascular disease 
contributions to AD
The links between cerebrovascular disease (CVD) and 
AD drawn from studies of comparative risk factors are 
extensive and have led to several interventional studies 
that hypothesize that AD may be a “vascognopathy”.64–68 
The interplay between PUFAs, cholesterol, CVD, and their 
interrelationship with the development of AD is a topic of 
extreme interest in the field. While many important factors 
are associated with both CVD and AD, this review will 
focus on the interrelationships of omega-3 PUFAs, cho-
lesterol, and apolipoprotein E (ApoE) status exclusively. 
Several excellent reviews and abundant primary literature 
exist on the interplay and synergism between CVD and AD 
Toxic  Aβ
production 
prevented
DHA
DHA prevents oxidation 
  of γ-secretase 
Toxic  Aβ
production 
prevented
DHA
DHA
 γ-secretase cleavage 
site blocked 
DHA
  α-secretase cleavage 
site blocked 
d) Inhibit fibrillation and aggregation of Aβ
c) Reduce oxidation and dysregulation
of γ-secretase     
b) Shield γ-secretase cleavage site 
a) Facilitate α-secretase actions  
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OO- 
Aβ
aggregation
prevented
Aβ  
Figure 3 Omega-3 PUFAs influence amyloidogenic processing through several distinct and interrelated mechanisms: a) facilitation of the interaction of α-secretase with APP 
to produce non-toxic fragments and prevent the formation of Aβ, b) shielding the essential recognition sequence and intramembrane cleavage site for γ-secretase, c) serving 
as a local sink for free radicals that reduce the enzymatic augmentation of γ-secretase activity that can be induced by free radical damage to the protein complex important 
for the regulation of normal γ-secretase function, and d) directly inhibiting fibrillation and formation of toxic oligomeric species of Aβ.Clinical Interventions in Aging 2010:5 51
Omega-3 fatty acids in AD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
mechanisms of neurodegeneration. The beneficial effects 
of omega-3 PUFAs in preventing CVD have been largely 
attributed to its role in interference with platelet aggregation, 
lowering cholesterol, and preventing atherosclerotic buildup 
in vulnerable blood vessels.
Omega-3 PUFAs, especially EPA, although not DHA, 
inhibit platelet aggregation and serve as effective anticoagu-
lants.69 These properties give rise to the major risks of omega-3 
PUFA supplementation that include an increased risk of 
bleeding diathesis, especially for those taking medications 
that further interfere with platelet aggregation or the clot-
ting cascade.16,70–76 While this property of EPA may be seen 
as deleterious, it is possible that antiplatelet activity could 
be responsible for the beneficial effects of omega-3 PUFA 
supplementation reported in many studies. There is often a 
discrepancy in the effect of omega-3 PUFA supplementation 
in humans based on the source such as pure DHA or fish oil 
products which include a combination of both DHA and EPA. 
Such disparate data could suggest that the antithrombogenic 
properties of EPA allow increased blood flow and supply of 
nutrients as well as increased removal of toxic metabolites 
and proteins from the brain that might otherwise augment 
the degeneration characteristic of AD. Definitive studies 
investigating such mechanisms are lacking currently but 
deserve further exploration.
The deleterious effects of cholesterol on cardiovascular 
health can be largely attributed to stimulation of atherogenesis, 
yet cholesterol serves several important functions and is an 
essential component of cellular membranes. The brain is the 
most cholesterol-rich organ in the human body. Cholesterol is 
not transported into the brain, as are fatty acids, but instead it is 
synthesized in the brain, largely within astrocytes. Like omega-3 
PUFA, cholesterol can be oxidized, but this is dependent on 
enzymatic rather than non-enzymatic pathways including the 
CYP46 system. Oxidized cholesterol is relatively stable com-
pared to the high chemical reactivity of F2-IsoPs and F4-NPs. 
Cholesterol is also readily eliminated through the blood brain 
barrier in an oxidized form, preventing its buildup and further 
oxidative damage. Cholesterol may directly increase the 
activity of β- and γ-secretases.77,78 High cholesterol exposure 
increases Aβ production, whereas low cholesterol exposure 
decreases Aβ production in cell culture and in transgenic 
mouse models of AD. The interplay between cholesterol and 
omega-3 PUFA in membrane stabilization and fluidity as well 
as in the development of atherosclerosis appears to be a critical 
factor influencing the development of AD.
Apolipoprotein E (ApoE) is the major carrier of choles-
terol in the brain. The ε4 allele of ApoE is the most potent 
risk factor for sporadic, late-onset AD characterized to 
date.67,79–82 ApoE is produced in astrocytes and its production 
is upregulated during development and regeneration of the 
CNS. ApoE is also directly implicated in the mediation of 
Aβ production. There are three primary alleles for the ApoE 
gene, ε3 which is the most common and neither imparts risk 
nor protection, ε2 which appears protective against AD, and 
ε4 that is associated with earlier onset and development of 
AD. ApoE e4 is a risk factor for increased serum cholesterol 
in both humans and animals. This effect can augment the 
production of toxic Aβ as described above. In addition, cho-
lesterol promotes atherogenesis, which is directly related to 
the development of AD pathology when present in the circle 
of Willis.83–86 ApoE has also been shown to enhance in vitro 
oligomer and fibril formation from Aβ monomers.87, 88 Direct 
interactions between ApoE and omega-3 PUFAs have not 
been fully elucidated. The interplay between omega-3 PUFAs 
and ApoE may be mediated by cholesterol levels and regula-
tory mechanisms rather than through a direct interaction.
Clearly, the relationship between CVD and AD, including 
the association of both high cholesterol levels and the pres-
ence of the ApoE ε4 allele, and omega-3 PUFAs deserves 
further study and should not be dismissed in favor of the 
alternative hypothesis that omega-3 PUFAs directly influ-
ence AD through reduction of oxidative stress or alterations 
in Aβ metabolism as described above.
Cross-sectional, epidemiological, 
and prospective cohort studies
Several studies of dietary intake of PUFAs have been pub-
lished in large cohorts of individuals with AD worldwide 
and demonstrate a largely positive effect of increased dietary 
intake with a reduced risk of AD (Table 1). This has been 
reviewed in part by Cole and colleagues and again by Cunnane 
and colleagues7,8 The weaknesses of these studies lie largely 
in the retrospective nature of the data collection and the con-
found of reporter bias in estimating dietary intake of PUFAs 
from food-frequency questionnaires (FFQ). Still several of 
these studies have validated their findings with quantitative 
measures of fatty acid composition in serum. Others have 
looked at prospective conversion to dementia that further 
reinforces the potential beneficial effects of PUFAs in slow-
ing or preventing AD conversion. A summary of the relevant 
findings from these studies and their inclusion of data on 
confounding variables are presented below.
In 1997, Kalmijn and colleagues published data from 
the Rotterdam Study that included 5,386 individuals that 
were non-demented at baseline.89 All completed a FFQ as Clinical Interventions in Aging 2010:5 52
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part of their baseline evaluation. High total fat, saturated fat, 
and cholesterol were associated with an increased risk of 
dementia, whereas fish consumption was inversely related to 
both all-cause dementia and more strongly with incident AD. 
High total and saturated fat intake was especially associated 
with vascular contributions to dementia in this study and was 
rigorously assessed with MRI. Specific quantitative measures 
of cholesterol and serum fatty acid profiles or ApoE genotype 
were not routinely performed or reported on in this study. The 
duration of the follow-up was quite short at 2.1 years.
The Rotterdam study re-examined their data in 2002 to 
include a longer follow-up period and increased the numbers 
of subjects with incident AD in this period (n = 197 of 5,396 
normal subjects at baseline).90 This study failed to replicate 
their original findings. No association between dietary 
intake of total, saturated, or trans-fat, cholesterol, omega-3 
or omega-6 PUFA was found in this analysis.
The Canadian Study of Health and Aging (CHSA) rigor-
ously examined plasma fatty acid profiles cross sectionally in 
a small cohort of 84 subjects in 2000.91 Plasma total PUFA, 
DHA, and n-3/n-6 ratios were lower in AD, other dementia, 
and individuals with cognitive impairment that were not 
demented (CIND). Omega-6 fatty acids were higher in AD 
and CIND cases than in normals and non-AD dementias. The 
authors concluded that low plasma PUFA levels may be a risk 
factor for all cause dementia. This study provided the first 
look at n-3/n-6 ratios and demonstrated a rigorous quantita-
tive application of methodology to study the association of 
cross sectional PUFA levels with cognitive status, albeit in 
a small select sample of the larger CHSA population.
The data were reanalyzed in 2003 including only a subset 
of the original 84 subjects in their earlier report (n = 65).92 
Included for the first time was an analysis of the potential 
effects of the ApoE ε4 allele in modulating the association 
of plasma PUFA concentrations and clinical status. While the 
study reported a lack of association of PUFA with cognitive 
status in the cross sectional analysis, EPA levels were report-
edly higher than controls in CIND, and DHA and total PUFA 
were higher in dementia cases in the prospective analysis. 
This association was strengthened in the subset on subjects 
that were not carriers of the ApoE ε4 allele. No association 
of ApoE status with PUFA concentrations was seen in normal 
control or CIND subjects.
In 2009, the CHSA published an updated report in 663 
cognitively normal subjects at baseline, followed prospec-
tively that included 149 incident cases of dementia at study 
end.93 This study again failed to show a significant associa-
tion of baseline plasma PUFA levels and risk of incident 
cognitive decline in this population. These effects were not 
altered by covariate adjustment for potential confounders 
such as ApoE status.
Barberger-Gateau and colleagues reported their findings 
from the PAQUID study in France in 2002.94 An FFQ was 
administered to 1674 subjects during the third wave of the 
study. Participants were followed up to 2, 5, and 7 years and 
1,416 had at least one follow-up visit revealing 170 incident 
cases of dementia. Fish and seafood consumption at baseline 
was inversely associated with risk of incident dementia. 
Other meat intake showed no benefit or a deleterious effect. 
Education confounded these results suggesting that the effect 
might be simply explained by higher educational status or 
that higher educational status was simply associated with 
higher fish and seafood consumption. This is an important 
consideration as education is a well recognized mediator of 
cognitive decline. The methods for this study lacked rigor 
and the findings were speculative at best.
Barberger-Gateau and colleagues evaluated dietary patterns 
much further by using data from the larger Three-City cohort 
Study in 2007.95 A total of 8,085 subjects from Bordeaux, Dijon, 
and Montpellier, France, who had at least one follow-up visit 
were included in the analysis. The authors found that weekly 
fish consumption was associated with a reduced risk of AD 
and all cause dementia only in ApoE e4 non-carriers. Regular 
consumption of omega-6 rich foods that was not balanced 
or compensated by omega-3 rich foods was associated with 
an increased risk of all cause dementia only among ApoE 
e4 non-carriers. This study importantly, re-emphasized the 
links between the potential benefits of omega-3 rich diets, 
dementia, and the relationship between omega-3 and omega-
6 fatty acid intake.
A small study from Japan was published in 2002 that 
included 25 patients with AD, 15 patients with vascular 
dementia (VaD) according to NINCDS-AIREN criteria, 
and 49 controls.96 Data were assessed from the administra-
tion of a standardized FFQ. This study demonstrated that 
energy intake exceeded demands in the dementia groups 
compared to controls. The dietary intake of AD and VaD 
subjects was similar with the exception of higher intake of 
animal fats in the AD vs VaD groups. This study reinforced 
the importance of low n-3/n-6 ratios in the development of 
dementia in Japan.
In 2003, researchers from Dublin Ireland presented a 
case-control study on 148 AD subjects and 45 cognitively 
normal controls.97 Applying the rigorous methodology of 
the CHSA study of 2000, the researchers relied on serum 
measurements of EPA, DHA, and total serum saturated Clinical Interventions in Aging 2010:5 54
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fatty acids. While all three measurements were significantly 
reduced in AD versus normal control sera in adjusted analy-
ses, only DHA and total serum saturated fatty acids were 
associated with Mini-Mental State Examination (MMSE) and 
Clinical Dementia Rating scale (CDR) scores in step-wise 
multiple regression analyses.
Morris and colleagues presented data from a FFQ 
administration to 815 subjects in the Chicago Housing and 
Aging Project (CHAP) in 2003.98 The study concluded that 
participants who consumed fish once a week or more had a 
60% reduced risk of AD compared to those who rarely, or 
never, ate fish. Total PUFA and DHA, but not EPA intake 
was associated with this reduced risk for AD. Intake of 
ALA, a precursor to DHA derived from plant rather than fish 
sources, was also protective, but only in ApoE ε4 carriers, in 
contrast to the positive effects of PUFA seen only in ApoE 
ε4 carriers in the CHSA study above. The reasons for this 
discrepancy were not explored further.
The CHAP study re-examined their data in 2005 with a 
larger cohort of 3,718 subjects that had completed at least 
two cognitive assessments.99 This analysis failed to confirm 
the previously robust findings of the initial analysis, but did 
again show a small effect of fish consumption which favored 
a 10% slowing of the rate of cognitive decline in subjects but 
did not appear to affect the cognitive state for individuals 
studied. ApoE status was not studied as a covariate in this 
iteration of the CHAP study data.
The Cardiovascular Health Cognition Study directly 
examined the association of fish intake (lean versus fatty) 
with dementia, AD, and VaD in relation to ApoE status in 
2,233 subjects in their 2005 report.100 The authors reported 
that while consumption of lean fried fish had no protective 
effect, the consumption of fatty fish more than twice a week 
was associated with a reduced risk of dementia and AD. 
Stratification by ApoE ε4 demonstrated that this effect was 
selective for non-carriers of the ε4 allele only.
The Framingham Heart Study examined plasma DHA 
levels at baseline in 899 subjects followed prospectively for 
a mean of 9.1 years.101 Over the study period, 99 incident 
cases of dementia were observed and increased baseline DHA 
levels were associated with a reduced risk of incident demen-
tia in this cohort. Adjustment for ApoE status increased the 
level of significance for this finding in this cohort composed 
of approximately 78% ApoE ε4 non-carriers.
The Atherosclerosis Risk in Communities (ARIC) 
study prospectively studied the association between plasma 
fatty acids and cognitive decline in 2,251 subjects enrolled 
between 1990–1992 and 1996–1998.102 Elevated PUFA 
levels were associated with reduced risk in decline in verbal 
fluency. No associations between PUFA levels and psycho-
motor speed or delayed recall were found. The association 
of reduced risk in verbal fluency decline with elevated PUFA 
levels was augmented in subjects who were hypertensive or 
hyperlipidemic. ApoE status was not a significant covariate 
in this analysis.
The Zutphen Elderly Study used a FFQ to assess dietary 
status of 210 participants from the Netherlands in 2007 and 
related this to subsequent 5-year cognitive decline as mea-
sured by the MMSE.103 This study demonstrated significantly 
less cognitive decline in fish consumers than non-consumers 
over the 5-year follow-up period. A linear relationship was 
found for intake of total PUFA and cognitive decline, with 
an average difference of 1.1 points decline on the MMSE per 
increased 380 mg/day of total PUFA in the diet.
The Older People and n-3 Long chain polyunsaturated 
fatty acid (OPAL) study examined 867 persons aged between 
70–79, without dementia, an MMSE score of 24–30, and not 
taking regular fish oil supplements.104 The study design was 
a cross sectional analysis of self-reported fish consumption 
and an extensive battery of neuropsychological test measures. 
While unadjusted analysis of these data revealed significant 
positive correlations between fish intake and delayed recall on 
the California Verbal Learning Test, after adjustment for age, 
gender, education and general health status, no significant 
association was seen. ApoE genotype was not reported, nor 
was an assessment of n-6 intake performed or considered as 
part of the analysis.
In 2008, Whalley and colleagues published their analysis 
of n-3 fatty acid erythrocyte membrane content and cogni-
tive variation in 113 cognitively normal volunteers enrolled 
in a birth cohort study in Scotland and followed over three 
longitudinal assessments at ages ∼64, 66, and 68 years.105 The 
study was designed to test the observation of Huang and col-
leagues,100 that ApoE status was an important determinant in 
modulating the effect of n-3 intake on cognitive status. Fish 
oil supplement use was equally distributed between ApoE 
e4 carriers and non-carriers. While cognitive benefits were 
associated with higher erythrocyte n-3 content, this associa-
tion was only significant in ApoE e4 non-carriers. The authors 
proposed a gene × environment interaction for cognitive aging 
and Alzheimer’s disease (AD) based on their findings.
The weaknesses of the above studies lie in the variable 
assessment of potentially significant confounders such as 
ApoE status and dietary intake of omega-6 PUFAs, saturated 
or trans- animal fats. Only 59% (10 out of 17 total studies) of 
the studies reported above assessed such confounds. Despite Clinical Interventions in Aging 2010:5 55
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this caveat, 70% (7 out of 10) of the studies that assessed 
ApoE status and 71% (5 out of 7) studies that assessed dietary 
n-6/saturated/trans fats found a significant impact of such 
confounders on the association of PUFA status with cognitive 
decline or dementia.
To place the above studies in the appropriate context of 
whether omega-3 PUFA supplementation should be pursued 
as a plausible therapy to treat or prevent AD, several points 
need to be considered. Of the population-based or cohort 
studies, 14 out of 17 showed a significant benefit of elevated 
omega-3 PUFA intake or measured plasma/serum levels in 
reducing the association with prevalent dementia, risk of 
cognitive decline, or the development of incident dementia. 
Two of the three studies that failed to show such an effect are 
from the CHSA cohort. The third showed a positive effect 
suggesting that either: 1) sampling bias; 2) methodological 
variability; or 3) marginal effects that straddle the level of 
significance are seen in this select study. In addition, 13 of 
the 16 studies used prospective follow-up of baseline data to 
examine the risk of incident cognitive decline or dementia 
rather than simply assessing a baseline association. Such 
strategies serve to further strengthen the association of 
omega-3 PUFA intake or plasma levels with cognitive status. 
The overwhelming data presented above favor a positive 
effect of omega-3 PUFA levels on cognitive status.
Despite the strengths of much of this data, the timing 
and duration of n-3 supplementation have yet to be deter-
mined. Such population and cohort based studies cannot 
take into account the possible need for more prolonged or 
lifelong dietary habits to define a benefit or association of 
n-3 supplementation with cognitive outcomes in the elderly. 
Such epidemiologic evidence for the prevention of cognitive 
decline and the development of dementia has been demon-
strated previously for both estrogen replacement therapy and 
non-steroidal anti-inflammatory use. Yet the prospective, 
randomized, clinical trials clearly demonstrated an increased 
risk rather than the postulated benefit related to duration of 
treatment. Evidence that dietary modification, or the use of 
n-3 supplements, to prevent cognitive decline or dementia 
is beneficial for the at-risk elderly population will require 
rigorous assessment in prospective, randomized, clinical 
trial designs.
Clinical trials of PUFA 
supplementation
Only 6 prospective studies of PUFA supplementation have 
been completed to date in the area of cognitive decline and 
dementia. Four of these are published and the most recent two 
have been presented in abstract form at the 2009 International 
Conference on Alzheimer’s Disease.
The first published study in 2004 included only 20 AD 
patients treated with 500 mg ethyl-EPA twice a day for 
12 weeks.106 This small sample size, short trial showed no 
effect on cognitive decline as would be expected given the 
study design. A significant increase in plasma and erythrocyte 
membrane EPA and total n-3 levels was demonstrated. No 
follow-up studies have been reported, and the relevance of 
EPA supplementation to brain health remains unclear. This 
study clearly demonstrated however that dietary supple-
mentation has a direct impact on circulating plasma levels 
of PUFAs.
A second study from Japan, published in 2006, examined 
the effects of 240 mg/day AA and DHA and colleagues 
240 mg/day olive oil in 21 randomized subjects with MCI 
(12 assigned to active study treatment and 9 assigned to the 
olive oil placebo).107 Ten subjects with organic brain lesions 
(cerebral infarction, hemorrhage, or traumatic brain injury 
greater than five years earlier), and 8 subjects with AD served 
as additional control groups and were not randomized. The 
subjects were followed over a period of 90 days of treatment 
and assessed before and after intervention. Primary outcome 
measures included the subtests of the repeatable battery for 
the assessment of neuropsychological status (RBANS). 
The MCI subjects randomized to active treatment showed 
an improvement on immediate memory and attention sub-
tests. Subjects with organic brain lesions also improved in 
immediate and delayed memory test scores. Placebo-treated 
MCI and actively treated AD subjects showed no significant 
improvements in any of the RBANS subtests. The authors 
concluded that AA and DHA supplementation may be 
beneficial in persons suffering from cognitive decline due 
to organic brain damage or age-related cognitive decline. 
This study showed promise but clearly suffered from major 
methodological flaws in study design, and so the conclusions 
drawn are subject to careful scrutiny and review.
In 2006, the first large-scale, well-designed, randomized, 
double-blind, placebo-controlled trial of omega-3 PUFA sup-
plementation was reported by Freund-Levi and colleagues.108 
This study included 204 subjects with mild to moderate AD 
receiving a cholinesterase inhibitor randomized to treatment 
with 1.7g DHA and 0.6 g EPA per day or placebo for 6 months 
and included a 6-month open label extension in which all 
subjects received the omega-3 PUFA treatment. Primary 
outcome measures included the MMSE and Alzheimer’s 
Disease Assessment Scale cognitive component (ADAS-
cog). No significant differences in these primary outcome Clinical Interventions in Aging 2010:5 56
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measures were observed between treated and placebo groups, 
however a subgroup analysis of mildly affected individuals 
(MMSE  27, n = 32) demonstrated a significant reduction 
in MMSE decline compared to the placebo subgroup. Similar 
effects were seen with active treatment in the 6–12 month 
period for the subjects with MMSE  27 treated initially 
with placebo. Of note, only 31% of the study cohort were 
ApoE ε4 non-carriers and the treatment effect of ApoE status 
was not assessed as the groups were matched in this regard. 
The authors concluded that the beneficial effects of omega-3 
PUFA supplementation may be dependent on cognitive status 
at time of treatment intervention with those in the earliest 
stages of disease benefitting most. A follow-up publication 
in 2009 failed to show significant effects on inflammatory 
or AD biomarkers in (CSF) from a subset of these patients 
(n = 35).109
Another small, randomized, double-blind, placebo-
controlled study from Taiwan was published in 2008.110 
The study group included 23 subjects with mild to moderate 
AD and 23 subjects with mild cognitive impairment (MCI) 
randomized to receive either 1.8 g/day omega-3 PUFA or 
placebo (olive oil) for 24 weeks of active study participa-
tion. Primary outcome measures included the ADAS-cog 
and the Clinician’s Interview-Based Impression of Change 
scale including caregiver-supplied information (CIBIC-plus). 
Improvement on the CIBIC-plus was seen for the active treat-
ment versus placebo group overall. ADAS-cog decline did 
not differ between treatment and placebo groups overall, but a 
subgroup analysis did demonstrate a beneficial effect of treat-
ment on the ADAS-cog in the MCI group alone. This study 
again recapitulated the positive effects of omega-3 PUFA 
supplementation on cognitive decline in early stage memory 
decline (MCI or early AD) seen in the Freund-Levi study.108 
No assessment or adjustment for ApoE was performed.
At the 2009 International Conference on Alzheimer’s 
Disease, the preliminary results of two major clinical trials 
with DHA were presented. The Memory Improvement with 
DHA Study examined the effects of DHA supplementa-
tion (900 mg/day) in a large, multi-center, double-blinded, 
randomized, placebo-controlled clinical trial with 485 cog-
nitively normal participants, with a mean age of 70 years, 
over a 6 month treatment period. DHA treatment significantly 
reduced total errors on the Paired Associates Learning (PAL) 
subtest of the Cambridge Neuropsychological Test Auto-
mated Battery®, which was reported as the primary outcome 
measure. The treated group experienced a doubling of plasma 
DHA levels and these levels were highly correlated with 
performance on the PAL. Both compliance and safety were 
excellent and distributed equally between arms. Data on dietary 
n-6 intake or ApoE status were not included in the presentation 
or abstract. The trial was considered positive overall suggest-
ing a benefit of DHA in preventing age–associated cognitive 
decline. Careful review of the study protocol, however sug-
gests that this primary outcome may have been selected after 
an interim analysis showed a potential signal, midway during 
the course of the trial, and that the original outcome measure 
was the global battery score, which was not significant. 
These observations cast doubt on the validity of the original 
conclusions of the study and further demand replication in 
a future study before the utility of DHA in preventing age 
associated memory decline can be assessed.
The Alzheimer’s Disease Cooperative Study DHA trial 
examined the effects of DHA (2 g/day) in a large, multi-cen-
ter, double-blinded, randomized, placebo-controlled clinical 
trial in 402 subjects with mild to moderate AD, mean MMSE 
20.7 ± 3.6, and 59% ApoE ε4 positive. This trial failed to 
meet its primary outcome measures of change in ADAS-cog 
and CDR sum of boxes overall and was considered a negative 
trial. Treated subjects had elevated levels of both plasma and 
CSF DHA demonstrating the effectiveness of this regimen 
in augmenting both peripheral and central DHA stores. Data 
on dietary n-6 intake were not included in the presentation or 
abstract. Planned secondary analysis of mild versus moderate 
stage AD failed to show a positive effect, in contrast to the pre-
viously discussed European trial conducted by Freund-Levi and 
colleagues.108 The planned secondary analysis of the effects of 
ApoE status on treatment effect demonstrated positive benefit in 
change on the ADAS-cog and a trend toward a positive effect on 
the MMSE, but not on the CDR sum of boxes in ApoE ε4 non-
carriers only. These trial results raised speculation on a possible 
pharmacogenomic interaction between ApoE status and DHA 
supplementation as has been suggested by others investigating 
the potential benefits of dietary DHA intake in cross-sectional, 
epidemiologic, and prospective cohort studies.
The prospective clinical trial data on omega-3 PUFA 
supplementation to date suggest a potentially positive effect 
of DHA supplementation on select persons within the study 
cohorts only. Emerging themes derived from these data 
include: 1) a potential augmentation of the beneficial effects 
of DHA in subjects with normal cognition or in the earliest 
stages of cognitive decline such as MCI or early AD; and 2) a 
potential role of ApoE status as a modulator of the effect of 
DHA supplementation in later stage patients. While defini-
tive answers to the potential roles of cognitive status and 
ApoE genotype influences are lacking, the results of these 
studies have generated much excitement to further explore Clinical Interventions in Aging 2010:5 57
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the potential benefits of omega-3 PUFA supplementation in 
slowing or preventing cognitive decline.
Ongoing clinical trials of PUFA 
supplementation
Several clinical trials investigating the potential cognitive 
benefits of DHA are underway and can be reviewed in detail 
on http://clinicaltrials.gov. Ongoing trials are investigating 
the effects of PUFAs on cognition in a wide range of condi-
tions including in-utero and normal toddler development, 
pediatric bipolar disorder, autism, post-operative cognitive 
dysfunction, cardiovascular disease, septic encephalopathy, 
post traumatic stress disorder, intractable partial seizures, and 
aging in the frail elderly. Of relevance to the current review, 
none are focused on assessing a selective response that may 
be dependent on ApoE status or involve AD directly, although 
the study of frail aging led by Bruno Vellas at the University 
Hospital in Toulouse, France could provide further insights 
into the cognitive decline associated with aging, mild cogni-
tive impairment (MCI), or even early AD depending on how 
many subjects reach such study endpoints by the end of the 
36 month trial period. Additional trials are currently in the 
planning stages and so further insights into the potential 
benefits of omega-3 PUFA supplementation in AD may be 
years away, but nonetheless they are being relentlessly pur-
sued by investigators across the globe that are not dismayed 
by clinical trial data presented to date.
Conclusion
Integrating ApoE pharmacogenomics, dietary n-6 
intake “pharmacoenvironomics”, and cognitive-status/
“pharmaconeuropsychomics” with our understanding of 
the neuroprotective effects of PUFA supplementation.
Data from the cross-sectional, epidemiologic, and pro-
spective cohort studies of the associations between dietary 
omega-3 PUFA intake and cognitive status have been 
largely positive. Dietary habits in these cohorts are likely 
longstanding rather than short-lived, as in a clinical trial 
paradigm. These data suggest three emerging themes and 
possible areas of future exploration: 1) dependence of the 
potential beneficial effects of omega-3 PUFA on cognitive 
status, with cognitively normal persons and those in the 
earliest stages of memory decline (MCI or early AD) show-
ing the greatest benefit; 2) a modulatory effect of dietary 
n-6 intake that alters the n-3/n-6 ratio and may negate the 
positive benefits of n-3 supplementation irrespective of n-3 
intake; and 3) a potential modulatory role of ApoE status 
that influences the dietary benefits of omega-3 PUFA on 
cognition. Incomplete assessment of these potential modulators/ 
confounders across studies prevents firm conclusions from 
being drawn.
Along these same lines, the prospective clinical trial 
data on omega-3 PUFA supplementation to date suggest a 
potentially positive effect of DHA supplementation on select 
persons within the study cohorts only. Emerging themes 
derived from these data include: 1) a potential augmentation 
of the beneficial effects of DHA in subjects with normal 
cognition or in the earliest stages of cognitive decline such 
as MCI or early AD; and 2) a potential role of ApoE status 
as a modulator of the effect of DHA supplementation in later 
stage patients. While definitive answers to the potential roles 
of cognitive status and ApoE genotype influences are lack-
ing, the results of these studies have generated considerable 
interest in the field for future exploration.
The field of pharmacogenomics is emerging as an 
important contributor to our understanding of responders 
and non-responders to a variety of therapeutic interventions 
in many human disease states. The potential modulatory 
effects of ApoE status on omega-3 PUFA associations with 
cognitive status may be a prime example of this phenom-
enon. The effects of lifestyle modifications or confounders 
that influence the therapeutic efficacy of certain medica-
tions are highly appreciated and need to be considered an 
example of pharmacoenvironomics, with the potential for 
n-6 intake to completely negate or abrogate the suggested 
beneficial effects of omega-3 PUFA supplementation on 
cognitive status. Future studies investigating the associa-
tion of omega-3 PUFA intake with cognitive status need to 
take these factors into account, ensuring adequate sampling 
between ApoE ε4carriers and non-carriers or even enriching 
study populations in non-carriers that may show maximal 
benefit. FFQ and plasma fatty acid analyses should pay 
strict attention to n-6 dietary intake in addition to the focus 
on omega-3 PUFA. Definitive studies in select populations 
(ie, ApoE e4 non-carriers with low dietary intake of saturated 
fat and n-6 fatty acids) may assist in the development of 
rationally-guided, individualized therapies for the subset of 
AD subjects that may benefit from omega-3 PUFA adminis-
tration. Such individualized therapy could potentially benefit 
the 60% of ApoE ε4 non-carriers in the global population 
of more than 35 million persons suffering from this disease 
(http://www.alz.co.uk/research/files/World%20Alzheimer
%20Report%20Executive%20Summary.pdf), or 21 million 
affected persons, if omega-3 PUFA supplementation were 
combined with a regimen of reduced saturated fat and n-6 
fatty acids. The potential influences of ApoE status on Clinical Interventions in Aging 2010:5 58
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omega-3 PUFA biology require further exploration and 
investigation. Linked through their basic roles in lipid biol-
ogy, ApoE genotype could greatly influence omega-3 PUFA 
concentrations, transport, metabolism, and sequestration in 
lipid raft environments essential for healthy neuronal func-
tion and synaptic maintenance. Alternative explanations 
could include combinatorial effects on the production of 
toxic Aβ species. While omega-3 PUFA augmentation might 
decrease the production of Aβ, the effects of the ApoE e4 
allele could overwhelm or negate such potential benefits of 
omega-3 PUFA supplementation. Further studies of the basic 
biology of omega-3 PUFA and ApoE genotype interactions 
are needed to answer these important questions.
Other considerations include the effect of timing omega-3 
PUFA supplementation over the lifespan. Several stud-
ies have convincingly demonstrated that omega-3 PUFA 
supplementation may be more beneficial if administered 
prior to or in the earliest stages of cognitive decline. It 
may be that increased omega-3 PUFA levels are protective 
against cognitive decline and AD, but later play no role 
in the pathogenic cascade of events that culminate in the 
clinical and biological expression of fulminate AD, even 
in the early stages of disease. Alternatively the beneficial 
effects of omega-3 PUFA augmentation may still exist, but 
simply be overwhelmed by the strength of the pathological 
processes responsible for AD once the disease has produced 
the clinical and biological manifestations of moderate or 
more severe disease. Lessons learned from the past might 
suggest a focus on earlier or even preclinical stages of AD as 
a target for omega-3 PUFA intervention. Such an approach 
has practical feasibility given the global shift in focus on 
AD to the earliest clinical MCI and even preclinical stages 
of AD that are being investigated by researchers.
Far from dampening scientific progress in our understand-
ing of the potential benefits of omega-3 PUFA intake, the data 
obtained from the many studies investigating dietary omega-3 
PUFA, while seemingly disparate and even contradictory 
at times, have resulted in an increased understanding of the 
potential importance of omega-3 PUFA biology in the CNS 
and its potential importance in abrogating both age-related 
cognitive decline and the development of AD. These insights 
should serve to spur much needed research in this area of 
neurodegenerative biology and advance our understanding 
of this devastating disease.
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In memoriam
William R Markesbery, MD, internationally known Alzheim-
er’s disease (AD) researcher, died on January 30, 2010, 
from complications of mycobacterium avium complex at 
the University of Kentucky (UK) Chandler Medical Center, 
shortly after co-authoring the present review on omega-3 
fatty acids in Alzheimer’s disease for the journal, Clinical 
Interventions in Aging. 
Among Dr Markesbery’s many achievements, the 
establishment of the UK Sanders-Brown Center on Aging 
in 1979 and its continued success over the last 30 years 
marks his legacy. Soon after the establishment of the Center, 
Dr Markesbery was awarded one of the first of ten federally 
funded AD Research Centers (ADCs) with a primary focus 
on neuropathology. He received 30 years of continuous 
NIH peer reviewed funding for his research and had over 
415 peer reviewed scientific publications. He served as 
the Chairman of the Medical and Scientific and Advisory 
Board of the Alzheimer’s Association and on the National 
Advisory Council at NIA. In the early 1980s, Dr Markesbery 
and collaborators published the first of several studies that 
disproved the prevailing theory that AD was caused by an 
accumulation of aluminum and other toxic metals in the 
brain. Subsequently he and his colleagues were among the 
first to show that oxidative stress is present early in AD. 
He later described the neuropathological manifestations in 
mild cognitive impairment -the earliest detectable clinical 
phase of AD. 
He received numerous awards for his work including 
the Award for Meritorious Contributions to Neuropathol-
ogy, the Irving H Shaw Award for Distinguished Service Clinical Interventions in Aging 2010:5 59
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in the Field of Health Care, the Medallion for Intellectual 
Achievement, UK Library Associates, and recognition by the 
Alltech Lecture Series, University College, Dublin. In 2009, 
Dr Markesbery received the prestigious Khachaturian Award 
from the National Alzheimer’s Association for advancing 
the field of Alzheimer’s disease. Bill said “I am grateful to 
have the opportunity to take part in the investigation of the 
most devastating disease that affects humanity. It has been 
a privilege to care for individuals with the disease, support 
the families and through research, strive to gain a better 
understanding of Alzheimer’s disease so that one day soon 
we will learn how to prevent the disease in those at risk and 
stop the progression of those with the disease.” 
Despite all his accomplishments and his illnesses in the 
past 15 years, Dr Markesbery remained a tireless researcher 
and compassionate clinician. He epitomized the meaning of 
a Southern gentleman and was proud to refer to himself as a 
7th generation Kentuckian. He was admired and respected 
by all for his humility, kindness, generosity, high standards 
in all he undertook, and patience. He always had the time to 
listen to and counsel anyone at any level. He will be greatly 
missed by family, colleagues, patients and students, but his 
love of learning, high standards, kindness, and desire to teach 
will never be forgotten.
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